Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Precision BioSciences ( (DTIL) ) just unveiled an update.
On August 6, 2025, Precision BioSciences announced results from its Phase 1 ELIMINATE-B clinical trial for PBGENE-HBV, a treatment for hepatitis B. The trial’s Cohort 1, which involved three patients receiving low-dose PBGENE-HBV, showed promising safety and efficacy results, with no serious adverse events and significant reductions in hepatitis B surface antigen levels. Cohort 2 is underway, with one patient completing three doses and two others receiving one dose each, showing similar safety profiles. The favorable outcomes have led to the recommendation to initiate Cohort 3, with further updates expected later in 2025.
The most recent analyst rating on (DTIL) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Precision BioSciences stock, see the DTIL Stock Forecast page.
Spark’s Take on DTIL Stock
According to Spark, TipRanks’ AI Analyst, DTIL is a Neutral.
The most significant factors influencing the score are the financial performance challenges and positive corporate events. While financial instability and negative profitability weigh heavily, positive momentum in strategic clinical programs provides optimism. Technical analysis indicates moderate bullish sentiment, but valuation concerns due to a negative P/E ratio and lack of dividends limit overall attractiveness.
To see Spark’s full report on DTIL stock, click here.
More about Precision BioSciences
Precision BioSciences operates in the biotechnology industry, focusing on developing gene editing therapies. The company is known for its proprietary ARCUS genome editing technology, which it applies to create treatments for various diseases, including chronic hepatitis B.
Average Trading Volume: 267,889
Technical Sentiment Signal: Sell
Current Market Cap: $53.89M
Find detailed analytics on DTIL stock on TipRanks’ Stock Analysis page.